Chemotherapy Foundation Symposium XXI: Innovative Cancer Therapy for Tomorrow

Last Modified: April 3, 2003

Share article


Conference Dates: November 12-15, 2003
Conference Location: Marriott Marquis Hotel, New York, NY


Sponsoring Group: Chemotherapy Foundation

Conference Web Page URL: www.mssm.edu/tcf

Topics Covered: Novel strategies for control and cure of breast, ovarian, prostate, GI, bladder, hematologic malignancies, melanomas, head and neck, lung and brain tumors, cancer research, chemo-prevention, monoclonal antibodies, informatics, molecular targeted agents.

Conference Objectives: Professional education for oncologists for control and cure of cancer.

Who Should Attend: Oncologists, immunologists, hematologists, radiologists, physicians with secondary in oncology, nurses, pharmacists, and other health care professionals

Conference Agenda: Practical applications for the medical oncologist of multimodality therapies in diverse neoplastic diseases. International faculty of clinical investigators present results of clinical trials, new combination chemotherapy regimens, tumor vaccines, gene chips, immunotherapy, agiogenesis inhibition, biomodulation and other developing biotherapies.

Registration Information: Abstracts are accepted from invited faculty only. Physicians, nurses, pharmacists are eligible for CE credits. Registration fees are $475 for physicians, $300 for pharmacists, and $150 for house staff, fellows, physician assistants, nursing personnel, and other health care professionals. Complimentary breakfasts, lunches , and receptions are included

Conference Fees: $475 for physicians, $300 for pharmacists, and $150 for house staff, fellows, physician assistants, nursing personnel, and other health care professionals.

Continuing Education: Yes

Miscellany: Simultaneous Spanish Translation


News
Use of androgen-deprivation therapy for non-evidence-based indications fell from 2003 to 2005

Nov 4, 2010 - Implementation of the Medicare Modernization Act, which led to reduced reimbursement for androgen-deprivation therapy for prostate cancer, appears to have substantially reduced the rate at which the therapy is used for inappropriate indications, according to research published in the Nov. 4 issue of the New England Journal of Medicine.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More